Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1163 of 5804
-
Tiny heart device could patch leaky valve without surgery
Disease control Recruiting nowThe purpose of this clinical trial is as follows. To assess the safety of the investigational medical device "Pivot Bridge" in participants aged 18 years or older with massive or greater functinal tricuspid regurgitation (TR) who have received medical therapy (diuretics/pharmaco…
Phase: NA • Sponsor: Tau-MEDICAL Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Cancer drug nivolumab tested in rare blood cancer
Disease control Recruiting nowInvestigate the efficacy and safety of ONO-4538 in patients with Richter's transformation
Phase: PHASE2 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New scan could reveal hidden lung scarring activity
Diagnosis Recruiting nowThe goal of this clinical trial is to gain more information about how fibroblast activation protein inhibitor (FAPI) binds to a certain type of cells in fibrotic lung tissue and how this information can be used to better diagnose and track fibrotic lung disease activity. Partici…
Phase: PHASE2 • Sponsor: University of Wisconsin, Madison • Aim: Diagnosis
Last updated Jun 27, 2026 11:01 UTC
-
New pill aims to tame flushing and diarrhea in rare cancer syndrome
Symptom relief Recruiting nowA Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. The purpose o…
Phase: PHASE3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
New drug aims to slow kidney failure in rare genetic disease
Disease control Recruiting nowAlport syndrome (AS) is a rare genetic condition that causes kidney disease, hearing loss, and eye abnormalities that occur due to changes in specific genes (COL4A3, COL4A4, and COL4A5). These genes help in producing an important protein called collagen. People with AS have a hig…
Phase: PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug GenSci139 enters human trials for advanced cancers
Disease control Recruiting nowThis is a phase I, two-part, multicenter, first-in-human study. The Part 1 study will assess the safety, tolerability, preliminary anti-tumor activities, PK profile, immunogenicity and biomarker of GenSci139 in participants with locally advanced or metastatic solid tumors, as wel…
Phase: PHASE1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New radioactive drug aims to halt bone metastases in advanced cancers
Disease control Not yet recruitingA multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, dosimetry and efficacy of BPR-6023021 in subjects with advanced solid tumors with bone metastases
Phase: PHASE1, PHASE2 • Sponsor: Chengdu Syncor Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Radioactive drug targets Hard-to-Treat melanoma in early trial
Disease control Recruiting nowThe goal of this trial is to see if this investigational drug is safe for adult patients with melanoma that has spread to other parts of the body or cannot be removed by surgery. It will also see if this investigational drug can shrink melanoma tumors in the body. The main questi…
Phase: PHASE1 • Sponsor: Alpha-9 Oncology USA Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Could a blood pressure cuff cut heart attacks and strokes?
Disease control Recruiting nowAtherosclerotic cardiovascular disease (ASCVD) is a group of disorders sharing atherosclerosis as a common pathological basis, primarily affecting the heart, brain, kidneys, and other peripheral arteries, leading to clinical syndromes characterized mainly by arterial ischemia. It…
Sponsor: General Hospital of Shenyang Military Region • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New Light-Activated gel aims to clear precancerous skin spots
Disease control Recruiting nowThis Phase 3, randomized, multi-center, evaluator-blind, vehicle-controlled study evaluates the efficacy and safety of reformulated Levulan Kerastick (aminolevulinic acid HCl 20%) combined with photodynamic therapy (PDT) for field-directed treatment of actinic keratosis (AK) on t…
Phase: PHASE3 • Sponsor: Sun Pharmaceutical Industries, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
AR goggles could help surgeons remove breast tumors more accurately
Disease control Recruiting nowThis clinical trial aims to evaluate whether an augmented reality (AR)-based medical imaging solution (SKIA-Breast) is non-inferior to conventional ultrasound-guided skin marking in guiding breast-conserving surgery in female patients with breast cancer. Participants will be rand…
Phase: NA • Sponsor: SKIA Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New injection aims to tackle Alzheimer's at its roots
Disease control Recruiting nowStudy to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment due to AD and mild AD dementia.
Phase: PHASE1, PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug BNT329 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThe main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are. The second goal of this study is to evaluate how well BNT329 w…
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New hope for bile duct cancer: drug may delay return after surgery and chemo
Disease control Recruiting nowThis study trial is a prospective, multicentre, exploratory, single-arm, open-label phase II study to evaluat ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New nanoparticle imaging trial aims to light up hidden tumors
Diagnosis Recruiting nowThis is an open-label, first-in-human, dose escalation study evaluating investigational drug PORPHYSOSMES (PS, pegylated porphyrin-lipid conjugate-containing nanoparticle suspension) and 64Cu-PORPHYSOMES (64Cu-PS, pegylated Copper-64 labelled porphyrin-lipid conjugate-containing …
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Diagnosis
Last updated Jun 27, 2026 08:09 UTC
-
At-Home brain zaps show promise for depression relief
Symptom relief Recruiting nowDepression is a prevalent and debilitating disorder. The most common treatments are antidepressant medications and talking therapies. However, for many individuals, these are not their treatment of choice. Furthermore, even following a full course of treatment with an antidepress…
Phase: NA • Sponsor: King's College London • Aim: Symptom relief
Last updated Jun 27, 2026 08:14 UTC
-
New 'Lattice' radiation aims to zap tumor pain better than standard therapy
Symptom relief Recruiting nowThe goal of this randomized, phase III trial is to to determine if Spatially Fractionated Lattice Radiotherapy (SFRT) known as LATTICE therapy, leads to a greater reduction in pain or discomfort compared with conventional Radiation Therapy (RT) in patients with large tumours. Thi…
Phase: PHASE3 • Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
Promising combo tackles rare blood cancer in early study
Disease control Recruiting nowThis is a prospective single arm, multi-center, real-world study to observe the efficacy and safety of ZR (Zanubrutinib combined with Rituximab) in the first-line treatment for patients with marginal zone lymphoma (MZL).
Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New pill could ease lupus kidney damage – trial underway
Disease control Recruiting nowA double-blind,placebo controlled,randomized Phase 2 study to evaluate the safety and tolerability of once-daily, oral administration of 200 or 300 mg HSK39297 tablets versus placebo in Patients With Lupus Nephritis
Phase: PHASE2 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Taurine trial targets long COVID brain fog
Symptom relief Recruiting nowThe COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating symptoms long af…
Phase: PHASE2, PHASE3 • Sponsor: University of Alberta • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC